Medical Health & Life Science Research News

Report explores the urinary incontinence therapeutics market: latest trends and insights by 2025

Urinary incontinence, an involuntary leakage of urine, is a very common problem especially among people over 50 years of age. As per the American Academy of Family Physicians (AAFP), over 26 million Americans experience urinary incontinence at some point in their lives.

- Advertising -

This condition depends on the incontinence type and severity, along with its causative reason. Weakened bladder, damaged pelvic muscles, and cancer are some of the causes of urinary incontinence.

- Advertising -

This problem if not treated, affects the social, economic, and emotional life of persons affected by it, as chronic urinary incontinence can have a serious impact on overall health. The urinary incontinence condition is diagnosed using urodynamic testing or pelvic ultrasound.

If diagnosed, the treatment for urinary incontinence involves a combination of various exercises along with medications.

The global urinary incontinence therapeutics market is expected to be driven by rising demand for treatment of urinary disorders, along with combinational therapies with improved pharmacokinetic and pharmacodynamic properties. Furthermore, rise in geriatric population, awareness initiatives along with invention of effective therapeutics from years of research and development by manufacturers, is expected to steer the growth of the global urinary incontinence therapeutics market.

However, difficulty in disease diagnosis, along with negligence about urinary incontinence disorders is anticipated to restrain the market.

The global urinary incontinence therapeutics market has been classified on the basis of urinary incontinence type, therapeutic class, and distribution channels. Based on the type of urinary incontinence, the market has been categorized into stress urinary incontinence, urge urinary incontinence, functional urinary incontinence, overflow urinary incontinence, and mixed urinary incontinence.

Among these segments, stress urinary incontinence affects more than 30 million Americans, and its prevalence is higher in women. Based on therapeutic class, the market has been divided into anticholinergic/antispasmodic agents, skeletal muscle relaxants, antidepressants, alpha blockers, and others.

The others segment includes, but is not limited to beta-3 adrenergic agonists, topical estrogens, and serotonin – nor-epinephrine reuptake inhibitors. Recent advances in these therapeutic classes include the marketing of M3 specific anticholinergic drugs, which have low side effects due to increased bladder receptor sensitivity.

Based on distribution channels, the global urinary incontinence therapeutics market has been segmented into hospital pharmacy stores, retail pharmacy stores, and online pharmacies.

The major challenge in the global urinary incontinence therapeutics market is the efficacy of these medications along with reducing their adverse effects. Recent new pharmacogenic advances in introduction of transdermal medications with better efficacy and tolerability than the conventional oral therapeutics serves as a major opportunity to the market.

Counseling efforts from manufacturers with the help of various social organizations or NGOs is seen as a rising trend in the global urinary incontinence therapeutics market, which in turn is expected to increase therapeutic treatment adoption.

In terms of region, the global urinary incontinence therapeutics market has been divided into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Asia Pacific is projected to experience exponential growth owing to increasing geriatric population, and increasing awareness about the treatment as well as diagnosis of overactive bladder conditions.

Make an Enquiry @ www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=22883

North America is estimated to dominate the global urinary incontinence therapeutics market due to new and technologically advanced products introduced in the market and increasing specialty research initiatives in the field of urinary disorders. The global urinary incontinence therapeutics market is anticipated to experience high growth in pharma – emerging regions as several local manufacturers have a robust pipeline in the field of urinary incontinence research, due to the increasing demand for economic and efficient medications.

Key players in the global urinary incontinence therapeutics market are Johnson & Johnson (Janssen Global Services, LLC), Pfizer Inc., Astellas Pharma, Inc., ALLERGAN, Abbott, Sanofi, Merck & Co., Inc., Takeda Pharmaceutical Company Limited, Cytori Therapeutics Inc., and Atlantic Therapeutics among others.

News From

Transparency Market Research - In-depth AnalysisTransparency Market Research
Category: Market Research Publishers and RetailersCompany profile: TMR provides a range of marketing and business research solutions designed for your specific needs. From off-the-shelf syndicated business And market research to made-to-order custom research, we serve our clients to fulfill their immediate as well as ongoing research requirements.      We specialize in the following areas:   Syndicated Research Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemical, energy, food & beverage ...